SU 1498
SU 1498
CAS: 168835-82-3
Molecular Formula: C25H30N2O2
SU 1498 - Names and Identifiers
SU 1498 - Physico-chemical Properties
| Molecular Formula | C25H30N2O2 |
| Molar Mass | 390.52 |
| Density | 1.100±0.06 g/cm3(Predicted) |
| Melting Point | 126 °C |
| Boling Point | 590.6±50.0 °C(Predicted) |
| Solubility | Soluble in DMSO. |
| Appearance | powder |
| Color | white to beige |
| pKa | 10.30±0.36(Predicted) |
| Storage Condition | -20°C |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
| In vitro study | SU1498 stimulates accumulation of phosphorylated ERKs in human umbilical vein endothelial cells and in human aortic endothelial cells in a manner that is dependent on the functioning of the upstream components of the MAPK pathway, B-Raf, and MEK kinases. The enhanced accumulation of phospho-ERKs is observed only in cells that have been stimulated with sphingosine 1-phosphate or protein growth factors; SU1498 by itself is ineffective. SU1498 blocks signal transduction from VEGFR2 in MS1 VEGF cells.In the presence of SU1498, levels of Ets-1 are decreased, suggesting that VEGF-VEGFR-2 interactions contributed to baseline levels of Ets-1 expression, and interruption of this autocrine interaction with SU1498 led to decreased expression of Ets-1. SU1498 treatment significantly impacts U87 cell proliferation and apoptosis. SU1498 induces a marked increase in lipids and a decrease in glycerophosphocholine. Accordingly, accumulation of lipid droplets is seen in the cytoplasm of SU1498-treated U87 cells. |
SU 1498 - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 2.561 ml | 12.803 ml | 25.607 ml |
| 5 mM | 0.512 ml | 2.561 ml | 5.121 ml |
| 10 mM | 0.256 ml | 1.28 ml | 2.561 ml |
| 5 mM | 0.051 ml | 0.256 ml | 0.512 ml |
Last Update：2024-01-02 23:10:35
SU 1498 - Reference Information
| biological activity | SU1498 is a KDR inhibitor with an IC50 of 0.7 μM, which can stimulate the accumulation of phosphorylated ERK1/2 in endothelial cells. |
| target | TargetValue KDR () |
| Target | Value |
| in vitro study | SU1498 stimulates accumulation of phosphorylated ERKs in human umbilical vein endothelial cells and in human aortic endothelial cells in a manner that is dependent on the functioning of the upstream components of the MAPK pathway, B- Raf, and MEK kinases. The enhanced accumulation of phospho-ERKs is observed only in cells that have been stimulated with sphingosine 1-phosphate or protein growth factors; SU1498 by self is ineffective. SU1498 blocks signal transduction from VEGFR2 in MS1 VEGF cells.In the presence of SU1498, levels of Ets-1 are decreased, suggesting that VEGF-VEGFR-2 interactions contributed to baseline levels of Ets-1 expression, and interruption of this autocrine interaction with SU1498 led to decreased expression of Ets-1. SU1498 treatment significantly impacts U87 cell proliferation and apoptosis. SU1498 induces a marked increase in lipds and a decrease in glycerophosphocholine. Accordingly, accumulation of lipid droplets is seen in the cytoplasm of SU1498-treated U87 cells. |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: SU 1498 Visit Supplier Webpage Request for quotationCAS: 168835-82-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: SU 1498 Visit Supplier Webpage Request for quotationCAS: 168835-82-3
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History